Hepatotoxicity of Chemotherapy
Paul D. King, Michael C. Perry · The Oncologist · 2001
After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.
Cited by 454 works. doi:10.1634/theoncologist.6-2-162
Authors
References
- Cancer: Principles and Practice of Oncology.
- A clinical review of bleomycin—a new antineoplastic agent
- Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
- Criteria of drug-induced liver disorders
- Drug-Induced Hepatotoxicity
- Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule
- 6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short- and Long-Term Toxicity
- Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients
- Mitomycin C: a review
- Clinical toxicity of interferons in cancer patients: a review.